BioSpace News Archive

Bausch + Lomb Corporation released a report of survey results from the company’s first annual Visionary Report, which was designed to identify new key insights into the value Americans place on their eyesight, as well as the ‘blind spots’ that may exist in the understanding and awareness of Age-related Macular Degeneration, a leading cause of vision loss for those over age 50 and the leading cause of blindness for the 65+ population.

Nanoscope Therapeutics Inc. , a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced full enrollment of its Phase 2 clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin.

ACELYRIN, INC. today announced a $300 million Series C financing to fund izokibep Phase 3 development in psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) through anticipated submission of biologic license applications (BLA).

Canonic Ltd., focused on the development of medical grade cannabis products and a wholly owned subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), announced today that it has signed a non-exclusive licensing agreement with leading Portugal-based cannabis cultivation and manufacturing company, GroVida Lda

Eligo Bioscience, a gene editing company, and Kantonsspital St. Gallen, one of Switzerland’s leading hospitals, announced today their strategic alliance to develop a gene editing therapy for inflammatory cardiac diseases induced by bacterial mimicry.

Lykan Bioscience and RoslinCT, a leader in Contract Development and Manufacturing for cell therapies, announced the formation of its inaugural Scientific Advisory Board (SAB).

Lyra Therapeutics, Inc. today announced that the first patients have been treated in Part 2, the randomized stage, of the Phase 2 BEACON clinical trial of LYR-220 in adult patients with chronic rhinosinusitis (CRS) who have had a prior sinus surgery.

Numinus Wellness is pleased to provide an update on the integration of the Novamin acquisition, which completed on June 10, 2022.

ESSA Pharma Inc. today announced the appointment of Philip Kantoff , M.D., to its Board of Directors.

Keynote speakers AbbVie, AstraZeneca, Boehringer Ingelheim, CSL Behring, and GSK headline one of the industry’s largest events for driving collaboration and innovation.